Across the intervention group, the pharmacist issued 588 treatment recommendations, approximately 95% of which were implemented by physicians. Investigators classified 287 identified problems as medication errors, including errors considered potentially serious.1
The intervention group also had a higher rate of detected medication administration errors, reflecting the additional opportunities for identifying problems through dedicated medication review rather than evidence of poorer medication safety.
These findings reinforce the value of pharmacist participation before medication-related problems result in patient harm. In hematologic malignancies, where patients frequently receive therapies requiring close toxicity monitoring, early identification of prescribing concerns and administration errors can support safer treatment delivery.
Economic Findings Strengthen the Case for Integration
A separate economic analysis of the same randomized trial examined the financial implications of providing dedicated oncology pharmacy services.
The estimated pharmacist program cost was $105 per patient across the 5-month study period. Investigators calculated an incremental cost-effectiveness ratio of $434 per ADR avoided, with a bootstrap 95% confidence interval of $281 to $956.2
Emergency department visits occurred in 28.6% of patients receiving pharmacist care compared with 37.4% of controls, while hospitalization rates were 23.1% and 28.6%, respectively. Although these outcomes favored the intervention, the findings do not establish that pharmacist involvement independently produced statistically significant reductions in acute care utilization.2
Because the analysis included only pharmacist program costs and was conducted at a single center, the results should not be interpreted as demonstrating net health system savings across all practice settings.
What the Findings Mean for Hematology-Oncology Practice
The trial contributes to a growing evidence base supporting pharmacist-led medication management. A 2026 systematic review of 33 studies found that pharmacist interventions consistently improved identification and resolution of medication-related problems, although effects on broader clinical outcomes remained less certain.3
The Hematology/Oncology Pharmacy Association’s 2026 scope of practice similarly emphasizes oncology pharmacists as direct patient care providers whose responsibilities extend beyond medication dispensing to active participation in treatment management.4
For outpatient hematology-oncology programs, the findings support evaluating how dedicated pharmacist time can be incorporated into existing clinical workflows. Medication reconciliation, toxicity assessment, and communication with prescribers represent practical opportunities to identify problems before they disrupt treatment.
The study’s single-center design and relatively short follow-up limit its generalizability, particularly across institutions with different staffing resources and patient populations. Larger multicenter investigations will be needed to determine whether similar benefits can be sustained over longer treatment periods.
Nevertheless, the reduction in ADRs provides a compelling argument for recognizing oncology pharmacists as an integral component of medication safety in hematologic cancer care.
